Abstract:Parvovirus B19 (B19V) is a human pathogenic virus, responsible for an ample range of clinical manifestations. Infections are usually mild, self-limiting, and controlled by the development of a specific immune response, but in many cases clinical situations can be more complex and require therapy. Presently available treatments are only supportive, symptomatic, or unspecific, such as administration of intravenous immunoglobulins, and often of limited efficacy. The development of antiviral strategies against B19V should be considered of highest relevance for increasing the available options for more specific and effective therapeutic treatments. This field of research has been explored in recent years, registering some achievements as well as interesting future perspectives. In addition to immunoglobulins, some compounds have been shown to possess inhibitory activity against B19V. Hydroxyurea is an antiproliferative drug used in the treatment of sickle-cell disease that also possesses inhibitory activity against B19V. The nucleotide analogues Cidofovir and its lipid conjugate Brincidofovir are broad-range antivirals mostly active against dsDNA viruses, which showed an antiviral activity also against B19V. Newly synthesized coumarin derivatives offer possibilities for the development of molecules with antiviral activity. Identification of some flavonoid molecules, with direct inhibitory activity against the viral non-structural (NS) protein, indicates a possible line of development for direct antiviral agents. Continuing research in the field, leading to better knowledge of the viral lifecycle and a precise understanding of virus–cell interactions, will offer novel opportunities for developing more efficient, targeted antiviral agents, which can be translated into available therapeutic options.

Antiviral alternatives against important members of the subfamily Parvovirinae: a review

Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

Novel parvovirus sublineage in the family of Parvoviridae

Identification of novel recombinants and proposed standard reference genomes for phylogenetic classification of canine parvovirus-2 (CPV-2): Comprehensive analysis revealing global evolutionary trait

Advances in the Development of Antiviral Strategies against Parvovirus B19

Antivirals against human polyomaviruses: Leaving no stone unturned

[Therapy of canine parvovirus infection - review and current insights]

Alternative antiviral approaches to combat influenza A virus

New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase

Recent Advances on Targeting Proteases for Antiviral Development

The genetic evolution of canine parvovirus – A new perspective

Antiviral peptides as promising therapeutic drugs

Antivirals with common targets against highly pathogenic viruses

Antivirals targeting paramyxovirus membrane fusion

Preclinical animal models to evaluate therapeutic antiviral antibodies

Current Progress in Antiviral Strategies.

A Route to Novel Antiviral Agents and New Therapeutic Approaches

Recent Advances in Novel Antiviral Therapies against Human Adenovirus

Old and Novel Enteric Parvoviruses of Dogs

Antiviral Chemotherapy in Avian Medicine—A Review

Anti-virus reagents targeting the capsid protein assembly